The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The effectiveness of ibrutinib flexible dosing regimens on TTNT in CLL/SLL
Nilanjan Ghosh, MD, PhD, Levine Cancer Institute, Charlotte, NC, shares insights into the effectiveness of ibrutinib flexible dosing treatment strategies on the time to next treatment (TTNT) for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). This real-world data study on over 3000 patients showed that dose adjustment of ibrutinib was not associated with an increased risk of initiating the next line of therapy (LOT) when compared with continuous standard dosing. This suggests that a flexible dosing approach may be used to increase the safety of treatment whilst maintaining its efficacy. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: AstraZeneca, Pharmacyclics, Janssen, Bristol Myers Squibb, Gilead Sciences, Kite Pharma, BeiGene, Incyte, Lava Therapeutics, Incyte, Roche/Genentech, Novartis, Loxo Oncology, AbbVie, Genmab, Adaptive Biotech, ADC Therapeutics; Research funding: Roche/Genentech, Bristol Myers Squibb, Gilead, Morphosys, AbbVie, Pharmacyclics.
